Novo Nordisk to acquire Akero Therapeutics for $4.7bn.

Novo Nordisk, a Danish pharmaceutical company, agreed to acquire Akero Therapeutics, a US clinical-stage biotech focused on metabolic liver disease, for $4.7bn. “MASH destroys lives silently - and efruxifermin has the potential to change that by reversing liver damage. If approved, we believe it could become a cornerstone therapy, alone or together with Wegovy® (semaglutide), to tackle one of the fastest-growing metabolic diseases of our time. This acquisition embodies Novo Nordisk’s relentless ambition to move faster, go further, and ultimately deliver on our commitment to pursue leadership in diabetes, obesity and their associated comorbidities,” Mike Doustdar, Novo Nordisk President and CEO.